1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Tian'an Pharmaceutical Co., Ltd.

Tian'an Pharmaceutical Co., Ltd.

TNPH
Tian'an Pharmaceutical Co., Ltd.US flagOther OTC
0.01
USD
- -
- -
125,962.00Market Cap
Tian'an Pharmaceutical Co., Ltd.
TNPH
(Other OTC)

Recent

price

0.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2004
2005
2006
2007
TTM
FRC
0.04
0.25
0.51
- -
0.76
Revenue per Share
0.01
0.08
0.11
- -
0.22
Basic EPS, GAAP
-0.16
-0.01
0.1
- -
0.18
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
0.39
0.07
0.16
- -
0.36
Book Value per Share
0.31
0.49
0.65
- -
0.96
Tangible Book Value per Share
14
14
14
- -
14
Basic Weighted Avg Shares
1
4
7
11
11
Sales/Revenue/Turnover
14.03
35.67
24.16
35.81
35.81
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
- -
1
2
3
3
Net Income, GAAP
12.18
17.18
15.55
15.03
15.03
Effective Tax Rate (%)
16.12
30.17
21.49
29.51
29.51
Profit Margin (%)
4
5
8
11
11
Working Capital
- -
- -
- -
- -
- -
LT Debt
6
9
10
15
15
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
32.47
91.6
86.32
86.32
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'07
Sep'07
Dec'07
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
14
Market Capitalization
36
42
56

Working Capital

FRC

•

in mil. unless spec.
Jun'07
Sep'07
Dec'07
Total Current Assets
11
12
12
Cash, Cash Equivalents & STI
7
7
8
Accounts Receivable, Net
2
3
3
Inventories
1
1
1
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
38.4%
Free Cash Flow
- -
- -
81.09%
Net Income, GAAP
- -
- -
106.74%
Sales/Revenue/Turnover
- -
- -
50.53%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2005
- -
1
1
2
4
2006
2
2
2
2
7
2007
2
3
2
3
11

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2005
-0.01
0.01
0.03
- -
0.08
2006
0.03
0.02
0.04
- -
0.11
2007
0.06
0.07
0.06
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2005
- -
- -
- -
- -
- -
2006
- -
- -
- -
- -
- -
2007
- -
- -
- -
- -
- -
Similar Companies
ANG Lifesciences India Limited (ANG.BO)
Oxurion N.V. (0G99.L)
Fredun Pharmaceuticals Limited (FREDUN.BO)
Tian'an Pharmaceutical Co., Ltd. (TNPH)
Sugi Holdings Co.,Ltd. (7649.T)
Hydrogen Hybrid Technologies, Inc. (HYHY)
Business
Tian'an Pharmaceutical Co., Ltd. is engaged primarily in the development, manufacture, and sale of traditional Chinese medicine (TCM) herbal products, including pallets, hard capsules, and soft ointments. The company's core product portfolio encompasses traditional Chinese herbal medicines, chemical drugs, biological products, and health-related products under proprietary brands. Tian'an Pharmaceutical serves customers mainly in China and engages in expanding healthcare services such as health check, health management, and chronic disease prevention through partnerships and advanced medical technologies. Founded in 2003 with headquarters in Reno, Nevada, the company has diversified its operations into e-commerce, health and wellness, agriculture, and food sectors in recent years. A major recent development includes Tian'an Pharmaceutical's agreement to acquire a 75% stake in a Chinese health products business, strengthening its footprint in the health and wellness market segment. The company continues to build competitive advantages by integrating R&D, advanced production techniques, and commercial capabilities, focusing on expanding both the TCM product lines and healthcare services to meet growing demand domestically and in overseas markets. Tian'an Pharmaceutical also maintains a strategic presence through joint ventures and investments aligned with innovative drug developments and healthcare service expansion.